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Abstract
Background: HIV vaccine trials generally require that pregnant women are excluded from participation, and contraceptive
methods must be used to prevent pregnancy during the trial. However, access to quality services and misconceptions
associated with contraceptive methods may impact on their effective use in developing countries. We describe the pattern
of contraceptive use in a multi-site phase I/IIa HIV Vaccine trial in East Africa (Uganda, Kenya and Tanzania) and factors that
may have influenced their use during the trial.
Methods: Pregnancy prevention counseling was provided to female participants during informed consent process and at
each study visit. Participants’ methods of contraception used were documented. Methods of contraceptives were provided
on site. Pregnancy testing was done at designated visits during the trial. Obstacles to contraceptive use were identified and
addressed at each visit.
Results: Overall, 103 (31.8%) of a total of 324 enrolled volunteers were females. Female participants were generally young
with a mean age of 29(67.2), married (49.5%) and had less than high school education (62.1%). Hormonal contraceptives
were the most common method of contraception (58.3%) followed by condom use (22.3%). The distribution of methods of
contraception among the three sites was similar except for more condom use and less abstinence in Uganda. The majority
of women (85.4%) reported to contraceptive use prior to screening. The reasons for not using contraception included access
to quality services, insufficient knowledge of certain methods, and misconceptions.
Conclusion: Although hormonal contraceptives were frequently used by females participating in the vaccine trial,
misconceptions and their incorrect use might have led to inconsistent use resulting in undesired pregnancies. The study
underscores the need for an integrated approach to pregnancy prevention counseling during HIV vaccine trials.
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Introduction
Women in Sub-Saharan Africa carry a disproportionately large
burden of the HIV infection. Young women (15–24 yrs) are four
times more likely to be HIV infected than are young men [1].
Despite the risk for HIV infection, women are less likely to benefit
from existing behavioral and biomedical HIV prevention interven-
tions due to social, cultural and economic barriers [2]. Developing
an effective woman-controlled intervention like a vaccine is
therefore a high priority to reduce their vulnerability to HIV. It is
thus of utmost importance that women in Sub Saharan Africa
participate in HIV vaccine trials since they stand to benefit most
from an effective HIV vaccine. In addition, their participation will
not only accelerate HIV vaccine development but also allow for
valid gender-specific assessment of efficacy and safety [3,4].
However, there are several challenges to female participation in
these vaccine trials [5]. One of the challenges has arisen from the
requirement that women of childbearing potential use effective
contraception during their participation in HIV prevention trials
[6,7].
There have been efforts to advance HIV vaccine research
globally and particularly in Sub Saharan Africa [8]. Since the first
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several HIV vaccine trials have been conducted in the region
[7,9]. Female participation in most of these trials, particularly in
East Africa, has been low [10]. In the first US Military HIV
Research Program (USMHRP) phase I HIV vaccine trial to be
conducted in East Africa, where both men and women presented
for enrollment screening in equal numbers, there was only 13%
female enrollment despite equivalent rates of eligibility.
HIV vaccine trials require that women of reproductive age use
contraception during the trial since little or no human data exist
regarding vaccine safety in pregnancy. Although there has been an
increase in contraceptive use in Sub-Saharan Africa, their use
remains relatively low compared to other parts of the
world[11,12,13]. Past studies have shown that 2–20% of women
in Sub–Saharan Africa use contraception covertly [14,15].
However recent literature on this subject is scanty. There are
various difficulties women face in accessing contraception. These
include lack of social support (including spousal support), low male
involvement, existing myths and fear of method side effects, low
socio-economic status, high levels of illiteracy and scarcity of
family planning services[7,16,17]. These same difficulties may
impact contraceptive use in vaccine trials further limiting the
number of female participants in these trials.
Assessing the level and factors influencing use of contraceptives
during HIV vaccine trials provides vital information for contra-
ceptive and pregnancy prevention counseling for purposes of
recruitment and retention of females in these trials. We describe
the pattern of contraceptive use at enrollment and factors that
might have influenced their use, among 103 female participants in
a phase I/IIa HIV Vaccine trial (RV 172) conducted at USMHRP
sites in East Africa, May 2006 to August 2007.
Methods
Study overview
RV 172 was a phase I/IIa HIV clinical trial to evaluate the
safety and immnunogenicity of a multiclade HIV DNA plasmid
vaccine VRC-HIVDNA016-00-VP, boosted by a Multiclade
HIV-1 Recombinant Adenovirus-5 vector vaccine, VRC-HI-
VADV014-00-VP, in uninfected adult volunteers in East Africa.
Participants were enrolled at the three USMHRP supported East
Africa HIV vaccine research sites. The Makerere University-
Walter Reed Project (MUWRP), in Kampala, Uganda, recruited
participants from the urban and semi-urban populations within a
radius of 20 kilometers of Kampala city. The Walter Reed Project-
Kericho (WRP-Kericho), located on the grounds of Kericho
District Hospital in Kericho Kenya, recruited from rural and
urban populations within a radius of 20 kilometers from Kericho
town. The Mbeya Medical Research Council (MMRP) located on
the Mbeya Hospital campus recruited participants from semi-
urban populations within a radius of 10km from Mbeya town in
Tanzania.
At all the three study sites, the informed consent process was
conducted over 2–7 days and consisted of a general information
session where participants were provided with general information
on HIV vaccine research, a briefing session to provide study details
and a one-on-one informed consent session to obtain written
approval to participate in study.
Pregnancy prevention counseling and contraceptive
access and use
At all the three study sites, detailed information about study
related pregnancy risks was given during briefing and the informed
consent sessions. Pregnant women, breast feeding women and
those desiring to become pregnant during the study were excluded
from participation. During the informed consent session and at
each clinic visit, study staff provided information on methods of
contraception, discussed individual contraceptive choices and
provided pregnancy prevention counseling.
Each participant confirmed either verbally or by documentation
to have used contraception for at least 21 days prior to enrollment.
An agreed on method of contraception for each participant, was
documented as part of eligibility. For the majority of participants
(73.8%), the information on contraceptive use was based on self
report although when possible efforts were made to verify the
information using family planning cards or medical records.
In an attempt to enhance access to various effective contracep-
tive methods, arrangements were made with family planning
providers to supply contraceptives that were not being provided at
the study sites. MUWRP, Uganda offered male condoms onsite
and referral to an offsite family planning service located 1 km from
the clinic, which provided a range of contraceptives. MMRP,
Tanzania and WRP-Kericho-Kenya are located on hospital
premises where family planning services are provided. MMRP
clinic offered male condoms only onsite while WRP-Kericho,
Kenya offered male condoms, oral contraceptives and injectable
contraceptives on site.
Participants had options to access contraceptives from the study
sites, or from their usual service providers and/or from the offsite
family planning providers. Contraceptive methods reported in this
study were those used by participants at enrollment. For the
majority of participants, there was no difference between
contraceptive method used at enrollment and during the study.
Only seven (6.8%) participants changed the methods of contra-
ception used during the study and these changes were mostly late
in the study and had no impact on the analysis for this article.
Blood pregnancy tests were done during screening, before each
vaccination, and 2–6 weeks following the last vaccination.
Pregnancy during the study vaccination period resulted into
withdrawal from the vaccination schedule.
Obstacles to contraceptive use identified by voluntary disclosure
were addressed during individual pregnancy prevention counsel-
ing sessions’ at each study site. To assist participants further
understand the different contraceptive methods used and to
explore barriers to contraceptive use and how best to address the
obstacles, a focus group discussion was held with participants at
the Uganda site. A pictorial family planning chart was used to help
participants better understand contraceptive use and enhance
individual and group pregnancy prevention counseling. The focus
group discussion was conducted later during the follow-up phase
of the study.
The study received scientific and ethical approvals from the
Walter Reed Army Institute of Research Human Use Research
Committee (WRAIR HURC) and from the National AIDS
Research Committee (Uganda), Kenya Medical Research Institute
Ethical Review Committee (Kenya) and the Mbeya Ethical
Review Committee and the National Ethical Committee/Medical
Research Coordinating Committee (Tanzania).
Data analysis
Frequency distributions and proportions were used to describe
participants’ prior contraceptive use at the study sites. The
proportions of participants using the different types of contracep-
tives and the pattern of use at the three study sites are described by
their social and demographic characteristics.
Binary logistic regression analysis was used to identify factors
including social and demographic characteristics, associated with
hormonal contraceptive use. For this analysis, adjusted Odds
Contraception in Vaccine Trial
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(95% CI) are reported. The data was analyzed using SAS software.
Results
Out of the 324 participants enrolled in the RV172 clinical trial,
103 (31.8%) were females. A higher proportion of females, 35 out
of 60(58 %) were enrolled at MMRP, Tanzania, compared to 38
out of 144(26%) at MUWRP, Uganda and 30 out of 120(25%) at
WRP-Kericho, Kenya. The female participants were generally
young with a median age of 29 years (18–47). About half (49.5%)
of all females were married. The majority of female participants
were self employed or had paid employment (56.3%), and had no
education or less than high school education (62.1%). Female
participants at the Tanzanian site were less educated with 94.3%
not achieving a high school level of education compared to 42.1%
and 50% for Uganda and Kenya respectively(see Table 1).
Contraceptive methods used at the three sites included
hormonal contraceptives, male condoms, Bilateral Tubal Ligation
(BTL) and abstinence. Hormonal contraceptives were the most
commonly used accounting for 55.3% at MUWRP, Uganda,
53.3% at WRP-Kericho, Kenya and 65.7% at MMRP, Tanzania
(Table 2). Depo-Provera was more commonly used (34%)
compared to other hormonal contraceptives (24.3%). For the
other forms of contraception, there was higher condom use at
MUWRP, Uganda (34.2%) compared to WRP-Kericho, Kenya
(10.0%) and MMRP, Tanzania (20.0%) whereas abstinence and
BTL were higher at WRP-Kericho, Kenya (36.7%) compared to
MUWRP, Uganda (10.5%), and MMRP, Tanzania (14.3%).
The majority of the female participants reported to have been
using contraception prior to being screened for the study; 19.4%
reported to have been using contraception for one year or less,
32.0% for more than one year, whereas 34.0% reported to have
used contraception for undetermined period of time. Only 14.6%
of the female participants initiated contraception for purposes of
participating in the trial.
The pattern of use was different among married participants
compared to single/ separated/widowed participants (Table 3).
Married women were more likely to use hormonal contraception,
OR 3.3 (1.34–7.93) and less likely to use male condoms, OR 0.3
(012–0.97). When adjusted for marital status, age, employment
status, education level attained and country were not associated
with male condom or hormonal contraceptive use (Table 4 and 5)
except for significantly less male condom use by Kenyan
participants, OR 0.2 (0.005–0.82).
Nine pregnancies were diagnosed at the three sites (Table 2).
Uganda reported more pregnancies (13.2%) compared to Kenya
(3.3%) and Tanzania (8.6%).
Seven out of the nine participants (77.8%) who became
pregnant reported using hormonal contraceptives. Five partici-
pants on hormonal contraception reported using Depo-Provera.
Of these participants, one reported to having agreed to use Depo-
Provera because the study required contraceptive use although she
had no intention of using it. Two participants had documentation
of duly completed family planning cards and maintained that they
had received all injections as required. One participant was
requested to use dual methods during the first two weeks of Depo-
Provera injection but disregarded the advice while the last
participant delayed re-administration of the Depo-Provera injec-
tion. The other participants on hormonal contraceptives were
using oral contraceptive pills.
Two participants relying on male condoms became pregnant.
One pregnancy resulted from inconsistent condom use while the
second pregnancy was due to a participant’s change of mind about
contraception in order to maintain a new relationship.
Barriers to contraceptive use identified during individual
counseling and the focus group discussions included, insufficient
knowledge on use of chosen contraceptive methods, lack of partner
support, and myths and misconceptions surrounding contraceptive
use. One participant on Depo-Provera reported intermittent use
due to a belief that injections are not required when experiencing
Depo-Provera induced amenorrhea. Another participant on oral
contraceptives was using them as morning after pill.
Other common misconceptions included contraceptive use
being a cause of congenital abnormalities, infertility, and loss of
libido, decreasing in vaginal fluids and delaying conception
regardless of type of contraception. Some nulliparous participants
chose to use condoms over hormonal contraception because of
fear of loss of fertility.
The majority of participants opted to continue with their family
planning service provider rather than be referred to a new service
provider. At MUWRP, Uganda and MMRP, Tanzania, the two
Table 1. Demographic Characteristics of Female Study Participants by Site
Characteristics Category All sites MUWRP Uganda WRP-Kericho Kenya MMRP Tanzania
n( % ) n( % ) n( % ) n( % )
All participants: - 103 38 30 35
Education: None/Unable to read 4 (3.9) 2 (5.3) 1 (3.3) 1 (2.9)
Less than high school /Primary 60 (58.3) 14 (36.8) 14 (46.7) 32 (91.4)
High school /Secondary 27 (26.2) 18 (47.4) 7 (23.3) 2 (5.7)
Tertially education/Degree 12 (11.7) 4 (10.5) 8 (26.7) 0 (0.0)
Marital Status: Married 51 (49.5) 18 (47.4) 14 (46.7) 19 (54.3)
Single 38 (36.9) 16 (42.1) 12 (40.0) 10 (28.6)
Separated/Widowed 14 (13.6) 4 (10.5) 4 (13.3) 6 (17.1)
Employment Status: Employed/Self employed 58 (56.3) 19 (50.0) 22 (73.3) 17 (48.6)
Unemployed 38 (36.9) 16 (42.1) 7 (23.3) 15 (42.9)
Student 7 (6.8) 3 (7.9) 1 (3.3) 3 (8.6)
Median Age (range): - 29 (18–47) 29 (19–47) 29 (20–43) 30 (18–47)
doi:10.1371/journal.pone.0005164.t001
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44 participants (97.7%) on hormonal contraceptives continued
accessing contraceptives from their usual family planning service
providers. Only one participant switched to accessing contracep-
tives from a new service provider. The main reasons why
participants preferred to continue with their usual family planning
service providers were that some participants had been getting
Depo-Provera injections for a number of years and did not find it
necessary to change given that the study was temporary and other
participants resided near the service providers and therefore found
it more convenient to continue with these providers. However, this
created another barrier since availability and accessibility to
quality contraceptives at outside service providers could not be
ensured.
Discussion
In this study, contraceptive use and effectiveness were assessed
in the context of participation in an experimental vaccine trial
which required use of effective birth control methods. The
observations may not therefore generalize to the population of
women as a whole but are relevant to conduct of experimental
studies of vaccines and potentially other products. The majority of
participants used hormonal contraceptives at all the three study
sites. The choice to use hormonal contraceptives particularly
Depo-Provera is perhaps a reflection of the pattern of contracep-
tive use in sub-Saharan Africa as described by Seiber et al (2007)
[11]. Marital status significantly influenced the pattern of
contraceptive use. Married participants preferred to use hormonal
contraceptives, which differs from what is previously reported [18].
The use of Depo-Provera would be ideal for clinical trials and
offers several benefits including convenience, covert use and
therefore a female controlled intervention with wide accessibility
[19]. However, the majority of participants who became pregnant
reported using hormonal contraception, including five of who
reported using Depo-Provera. This demonstrates the existing
challenge to effective contraception or self report of contraceptive
use in clinical trials. Since hormonal contraceptives were not
routinely offered on site and most participants desired to continue
with their family planning service provider where their availability,
accessibility or quality could not be assured, it is possible that this
limited their optimal utilization. It also makes it difficult for
investigators to accurately verify information given by participants
about contraceptive use. This could suggest better utilization if
contraceptives are provided on site or establishing a clear referral
mechanism to a reliable family planning provider to ensure access
to quality methods and their consistent use. It could also be
important to use objective measures such as a requirement to
Table 2. Duration of Contraceptive use prior to Screening, Contraceptive Methods Used at enrollment and Pregnancies Reported
Characteristic Category All sites MUWRP Uganda WRP-Kericho Kenya MMRP Tanzania
n(%) n (%) n (%) n (%)
All participants: 103 38 30 35
Duration of contraceptive
use prior to screening:
#1 year 20 (19.4) 4 (10.5) 11 (36.7) 5 (14.3)
.1 year 33 (32.0) 11 (28.9) 7 (23.3) 15 (42.9)
Unknown 35 (34.0) 17 (44.7) 9 (30.0) 9 (25.7)
None used 15 (14.6) 6 (15.8) 3 (10.0) 6 (17.1)
Contraceptive at enrollment: Hormonal 60 (58.3) 21 (55.3) 16 (53.3) 23 (65.7)
Condoms 23 (22.3) 13 (34.2) 3 (10.0) 7 (20.0)
Other (Abstinence &
BTL)
20 (19.4) 4 (10.5) 11 (36.7) 5 (14.3)
Pregnancies (rates): - 9 (8.7) 5 (13.2) 1 (3.3) 3 (8.6)
doi:10.1371/journal.pone.0005164.t002
Table 3. Pattern of Contraceptive Use at Enrolment by Selected Demographic Factors (All Sites)
Demographic
factor Category
Total # on
Contraception
# Using Hormonal
Contraceptives (%)
# Using
Condom (%)
# Using Other
Contraceptives (%)
Occupation: Employed 58 30 (51.7) 13 (22.4) 15 (25.9)
Unemployed/student 45 30 (66.7) 10 (22.2) 5 (11.1)
Marital status: Married 51 37 (72.5) 8 (15.7) 6 (11.8)
Single/Separated/widowed 52 23 (44.2) 15 (28.8) 14 (26.9)
Age: ,24 33 18 (54.5) 9 (27.3) 6 (18.2)
25–34 44 28 (63.6) 11 (25.0) 5 (11.4)
.35 26 14 (53.8) 3 (11.5) 9 (34.6)
Education: Less than High School 64 40 (62.5) 14 (21.9) 10 (15.6)
High School and above 39 20 (51.3) 9 (23.1) 10 (25.6)
doi:10.1371/journal.pone.0005164.t003
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use.
A pregnancy rate of 8.9% in the study is within range of 3–15%
risk of pregnancy among typical hormonal and condom users in
the first year [20]. A further reduction in number of pregnancies in
phase I/II vaccine studies would be desirable and calls for an
integrated approach to pregnancy prevention including strategies
to identify and address factors that inhibit ideal use.
It is possible to conclude that the higher pregnancy rates at
MUWRP, Uganda is a reflection of Uganda’s high fertility rate of
6.6 compared to 5.0 for Kenya and 5.3 for Tanzania[21] however,
this is less likely since those that desired pregnancy were excluded
and ongoing pregnancy prevention counseling was given during
the trial. Moreover, many women were already on contraception
prior to study screening. Changes to women’s desire to have
children during the study could also be a possible explanation.
Although practiced in a few participants, abstinence alone was a
reliable method when chosen as an option, but investigators need
to regularly review participant’s adherence to this method and
intervene with an alternative promptly when sexual activity is
Table 4. Use of Hormonal Contraceptives by Participant Characteristics*
Characteristics Category -n- #Using Hormonal Contraceptives (%) Adjusted OR [95%CI]
All participants: - 103 60 (58.3) -
Marital Status: Single 38 17 (44.8) 1.0
Married 51 37(72.5) 3.3 [1.34–7.93]**
Separated/Divorced 14 6 (42.9) 0.9 [0.27–3.19]
Age (yrs): 18–30 64 38 (59.4) 1.0
31–49 39 22 (56.4) 0.7 [0.30–1.71]
All ages 103 60 (58.3) 0.97 [0.91–1.03]
Education: Primary or none 64 40 (62.5) 1.0
Secondary or higher 39 20 (51.3) 0.8 [0.35–1.97]
Occupation: Employed 58 30 (51.7) 1.0
Un-employed 38 26 (68.4) 1.4 [0.54–3.57]
Student 7 4 (57.1) 1.7 [0.31–8.91]
Country: Uganda 38 21 (55.3) 1.0
Kenya 30 16 (53.3) 0.9 [0.34–2.54]
Tanzania 35 23 (65.7) 1.5 [0.56–4.05]
*Response variable coded as: 0=Did not use hormonal contraceptives, 1=Used hormonal contraceptives.
**Significant observation.
doi:10.1371/journal.pone.0005164.t004
Table 5. Previous Condom Use as Contraception by Participant Characteristics*
Characteristics Category -n- #Using Condom (%) Adjusted OR [95%CI]
All participants: - 103 23 (22.3) -
Marital Status: Single 38 13 (34.2) 1.0
Married 51 8 (15.7) 0.3 [0.12–0.97]**
Separated/Divorced 14 2 (14.3) 0.3 [0.06–1.74]
Age (yrs): 18–30 64 16 (25.0) 1.0
31–49 39 7 (17.9) 0.8 [0.27–2.28]
All ages 103 23 (22.3) 0.99 [0.92–1.07]
Education: Primary or none 64 14 (21.9) 1.0
Secondary or higher 39 9 (23.1) 0.7 [0.20–2.20]
Occupation: Employed 58 13 (22.4) 1.0
Un-employed 38 7 (18.4) 0.7 [0.23–2.35]
Student 7 3 (42.9) 1.4 [0.23–8.14]
Country: Uganda 38 13 (34.2) 1.0
Kenya 30 3 (10.0) 0.2 [0.05–0.82]**
Tanzania 35 7 (20.0) 0.5 [0.18–1.63]
*Response variable coded as: 0=Did not use condom for contraception, 1=Used condoms as contraception.
**Significant observation.
doi:10.1371/journal.pone.0005164.t005
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effective method was rarely used given the average age of
participants. The small numbers involved in the sub-analysis
however limit the generalizability of these results.
Myths and misconceptions to contraceptive use continue to be
barriers to their effective use. Although their influence was not
measured in quantitative terms, it is possible that they impacted
contraceptive use. There is a need to identify and address them on
an ongoing basis during pregnancy prevention counseling. We
found group discussions to be a better forum for disclosing
misconceptions regarding contraceptive methods than individual
counseling, which could probably be due to social desirability that
can occur during individual counseling, since participants may not
want to be viewed as non study compliant. In addition, group
discussion allows debate and expression on issues outside the
context of a study.
Conclusion
The study reflects the contraceptive experience and effectiveness
among women who participated in an HIV vaccine trial which
required contraception during the study. Only a minority of
women entering the vaccine study initiated contraception at the
time of study entry. Obstacles to successful contraception may
include misconceptions about contraceptive methods among
volunteers and ineffective administration of methods by partici-
pants or family planning providers. Mitigation of these obstacles
may include more intensive and recurring discussion of contra-
ceptive technologies to improve participant knowledge and
acceptance. In addition, integrating provision of family planning
services with research activities may ensure appropriate use of
quality contraceptive products.
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